At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 529 enrolled
Drug / intervention
Nivolumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma
In Brief
A Phase 3 clinical trial evaluating Nivolumab, Bevacizumab, and 1 other intervention for Recurrent Glioblastoma. Completed, enrolled 529 participants across 112 sites in 12 countries.
Detailed Summary
The purpose of the study is to compare the efficacy and safety of nivolumab administered alone versus bevacizumab in patients diagnosed with recurrent glioblastoma (a type of brain cancer, also known as GBM), and to evaluate the safety and tolerability of nivolumab administered alone or in combination with ipilimumab in patients with different lines of GBM therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Glioblastoma
CountriesAustralia, Belgium, Denmark, France, Germany, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartFeb 2014
Primary CompletionJun 2019
Study CompletionJun 2024
TodayJul 2026
First PostedDec 23, 2013
Enrollment StartFeb 7, 2014
Primary CompletionJun 17, 2019
Study CompletionJun 21, 2024
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 12.5 years ago
Interventions
Nivolumabbiological
specified dose on specified days
Bevacizumabbiological
specified dose on specified days
Ipilimumabbiological
specified dose on specified days